Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Interested in seeing what is left of the Cult of Leo and who the last one to remain in the cult will be....All hail B, the .0002 wonder drug.
Once again, the reason you are here IS??????????
Can you not see that much has happened since 2013 and it has all been bad....
Facts…: Stock isn’t moving up nor does it have excellent potential. Bashers aren’t here to bring the price down or increase their short position as the stock isn’t even tradable.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175087180
Sure, that would definitely explain the numerous daily postings on a sub penny stock by you and the rest here with a similar outlook as opposed to actual shareholders. Make complete sense to me.
That's assuming that somebody finds some value in IPIX. When IPIX trades for less than $50 a day I don't think people are screaming to own this ticker. Do you know how many companies have come back after trading under a penny? I'm not sure myself but I would bet not many, if any at all. All of the missed filings, the lack of board etc, etc, etc...the list goes on. I believe people are waiting for another company to buy B which if it were to happen don't you think it would have happened by now?
It is because Brilacidin will become a blockbuster drug and they know it.
And the detractors will never honesty answer the question as to why!
No problem, we know why.
Personally I come for the files and stay for the triallings.
I don't know about anyone else but I come for the trials and stay for the filings. Woohoooo!
As worthless as you and others state that B is, something is bringing you here everyday!!!!!!
The reality is B is worthless. This is a fact proven by the share price & market cap. There’s no denying that fact regardless of how many graduate students dip shit in a dish as a requirement of their graduate program.
If B is so good, why is IPIX trading at the .0001/.0002 level?
"the combinations of MUT056399 and brilacidin or eravacycline will be selected for the efficacy test in the chronic wound infection mice model"
IPIX drugs don't have the best history with sick mice:
Whoops! I was going to post an image of those poor mice that were futilely tortured with Prurisol but the CEO disappeared it. Now he seems to have made himself disappear.
POOF gone! A real wizard.
What's next for IPIX? Thoughts?
"In the virus trial we know Brilacidin arrived too late to help."
Huh? Please explain. I thought it just plain didn't work.
"Further investigations involving drug combinations identified five synergistic drug combinations"
"Regards to time-kill and biofilm assays, the combinations of MUT056399 and brilacidin or eravacycline will be selected for the efficacy test in the chronic wound infection mice model."
Wow now FIVE synergistic drug combination also Cronic wound infection is certainly new.
SitTight There are dozens of these articles floating around. All test tube/petri dish observations .the drug fails when used in human trials..
Not bashing - just facts.
Another Nature.com article about Brilacidin just dropped:
Screening of the Pandemic Response Box library identified promising compound candidate drug combinations against extensively drug-resistant Acinetobacter baumannii
BARDA looking for new antifungals/antibacterials in AMR fight
LOL. Like this company, French is fried.
And your point is?
Ehrlich doesn’t give a tuppenny toss about people dying from infectious diseases.
He’s too busy counting his millions (that he stole from IPIX shareholders) by the pool at his Florida McMansion.
Antimicrobial resistance deaths could reach 39M 2025-2050
realscottsmith Are you hoping for this. If you are, you are not alone.
https://www.aol.com/hundreds-hezbollah-pagers-explode-apparent-151059377.html
Anyone know if Leo carries a pager?
Thanks, but the credit goes to......
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174262110
Someone on another board asked "What will happen to Brilacidin?" and I think that might be the answer....Penn might try to license it to someone else. But I think the underlying patents may have been abandoned.
Let's ask Frenchie! The answer must be somewhere in one of those billions of Google search returns.
Interesting find. The final dagger...although not so sure anyone would want B after the Flying Dutchman of Drugs killed off PolyMedix and IPIX.
$3 will soon be more than the entire Ehrlich debacle is worth....
re: The Brilacidin license.
Termination by Penn. Penn may terminate this Agreement on written notice to Licensee if any of the following events of default (“Default”) occur:
".25.1 If Licensee: becomes insolvent, bankrupt or generally fails to pay its debts as such debts become due; is adjudicated insolvent or bankrupt; admits in writing its inability to pay its debts; or shall suffer a custodian, receiver or trustee for it or substantially all of its property to be appointed and, if appointed without its consent, not be discharged within sixty (60) days; makes an assignment of all or substantially all of its assets for the benefit of creditors; or suffers proceedings under any law related to bankruptcy, insolvency, liquidation or the reorganization, readjustment or the release of debtors to be instituted against it and, if contested by it, not dismissed or stayed within thirty (30) days; "
Loss of the appeal will trigger the above unless the Company can find $1.4M between the cushions of the couch it doesn't have.
Has IPIX only traded about $3 worth of shares today? SMH
People try to educate those defending worthless stocks because of the psychological and financial risks involved. When someone defends a bad investment, they might be experiencing cognitive biases, such as *loss aversion* or the *sunk cost fallacy*. These biases cause people to hold onto losing investments because they don't want to admit failure or accept the loss.
Educating them can help provide a clearer perspective, encouraging more rational decision-making and protecting them from further financial damage. The goal is often to foster critical thinking, prevent emotional decision-making, promote healthier investment strategies in the future, and alerting others to stock scams. Reference https://investorshub.advfn.com/boards/read_msg.aspx?message_id=171556989
When people defend stocks that have become worthless, it can be tied to emotional attachment, pride, or the psychological discomfort of acknowledging a loss. Here are several reasons why others try to educate them:
1. **Cognitive Biases**: As mentioned, biases like the *sunk cost fallacy* (holding onto something because they've already invested a lot) or *confirmation bias* (seeking information that supports their belief) cloud judgment. Educators aim to counteract these biases, helping investors recognize the reality of their situation.
2. **Avoiding Further Loss**: By educating them, people hope to prevent further bad decisions. Defending a worthless stock can lead to additional investments in the same failing asset or similar risky ventures, increasing financial losses. Teaching sound investing principles, like cutting losses, can save future wealth.
3. **Emotional Well-being**: Losing money in stocks can trigger denial, anxiety, or frustration. Those defending their bad investment may feel isolated or judged, so education is often an attempt to offer support, helping them understand that poor investments happen to everyone. It provides an opportunity for personal growth and emotional resilience.
4. **Encouraging Financial Literacy**: Many people defending bad investments may not have a strong background in financial literacy. Educators see this as a chance to help them understand market risks, diversification, proper research, and risk management strategies to make more informed decisions next time.
5. **Avoiding Scams and Manipulation**: In some cases, stocks become worthless due to pump-and-dump schemes, where individuals are misled into buying overhyped stocks. Education is a way to protect people from falling into these traps again by teaching them how to spot fraudulent practices.
6. **Long-term Thinking**: Helping someone understand why defending a worthless stock may be harmful is often an attempt to instill long-term investment thinking. Shifting from short-term emotional reactions to a disciplined, researched approach can set up the individual for better financial health in the future.
7. **Social Responsibility**: In some cases, those defending worthless stocks may share their beliefs with others, spreading misinformation or misguided optimism. Educators often intervene to prevent this cycle, ensuring that others don't fall into the same trap.
Ultimately, the goal of educating such individuals is to foster financial discipline, rational decision-making, and self-awareness, which are crucial for sustainable wealth building.
People who defend stocks that become worthless after investing in them may do so for several reasons, ranging from psychological to financial motivations. Here are some common factors:
1. **Cognitive Dissonance**: Once people have invested in a stock, especially if they've invested heavily, admitting it's a bad or fraudulent investment conflicts with their belief that they made a wise choice. To reduce this discomfort, they rationalize or defend the investment.
2. **Sunk Cost Fallacy**: Investors often feel that because they’ve already spent money, time, or effort, they should continue defending their choice, even when new information shows the stock is crooked or failing. They believe they can eventually recover losses or even make a profit.
3. **Emotional Attachment**: People often get emotionally attached to their investments. After putting faith in a company, they might overlook red flags because they’ve tied their self-worth or financial hopes to the success of that stock.
4. **Fear of Financial Loss**: Investors might defend a crooked stock out of fear that negative publicity could drive prices down even further, leading to additional losses. In defending it, they may hope to stabilize its value or delay an inevitable decline.
5. **Influence of Community or Social Pressure**: If the stock is part of a broader "meme stock" trend or has an active online following, investors might feel pressured by that community to defend the stock, even when it’s failing or embroiled in controversy.
6. **Overconfidence**: Some investors might believe they know more than others and that the market or regulators have misunderstood the stock. They could convince themselves that they see the “real value” while others are too cautious or uninformed.
7. **Misinformation or Denial**: In some cases, investors may not fully understand that the stock is involved in fraudulent activities or poor practices. They may believe false narratives, often spread by company insiders or promoters, that the stock is misunderstood or unfairly attacked.
While defending a stock may feel like protecting one's investment, it often blinds investors to risks and realities, potentially leading to greater losses in the long run.
"...statements involve risks, uncertainties and assumptions that could cause actual results and experience to differ materially from anticipated results and expectations expressed in these forward-looking statements." Lost It All Leo was on point with this line. All his exaggerations and hype (most evident with Kevetrin) amounted to nothing but failure, underscoring the failure of his one-man fiasco.
I rather think you missed the point of my post. Perhaps you should read it again.
Hey Cap'n obvious, all PR's on the OTC include this statement...
It's called SOP.
Standard operating procedure.
TheHound As did "RUNNING GIRL"
None of the ipix bag-holders have the gumption to sue Leo.
Good news for the litigious!
In his misleading PRs IPIX’ CEO always includes a “safe harbor” statement:
Ostrich Ehrlich has buried his empty head in the sand....
Unfortunately the appeals court does not provide links to the actual documents in their docket. What we do know is that an appeal is a legal argument, not a factual one, the facts having been established in the original case. It's my understanding that they can no longer be argued.
What that means is the pages and pages of crap that Dwyer has just filed must refer to previous cases in which the company feels that their legal arguments prevailed.
I doubt that Cummins will bother with a case by case response.
It’s fucking gone to plan! Bagholders are fucked!
Your guess is as good as mine. I know a couple of people who have spoken to Leo in the past via email and phone calls and each person has said he does not answer anymore. So it’s anyone’s guess.
Where the fuck is our 4 million bucks. This son of a bitch has to go to jail.
Followers
|
976
|
Posters
|
|
Posts (Today)
|
8
|
Posts (Total)
|
403510
|
Created
|
05/10/08
|
Type
|
Free
|
Moderators zandant sunspotter snayeman loanranger frenchbroad |
Innovation Pharmaceuticals Inc. (IPIX)
$IPIX NEWS - http://ipharminc.com/press-release
SEC Filings https://www.sec.gov/cgi-bin/browse-edgar?company=Innovation+Pharmaceutical&owner=exclude&action=getcompany
From the most recent 10-K:
There are doubts about our ability to continue as a going concern.
We have generated revenue of $0 and $18,000 for the fiscal years ended June 30, 2023 and 2022, respectively and have an accumulated deficit of $125.3 million through June 30, 2023. These factors raise substantial doubt about our ability to continue as a going concern.
We need to raise substantial additional capital in the future to fund our operations and we may be unable to raise such funds when needed and on acceptable terms, which could prevent us from fully implementing our business, operating and development plans.
We currently have an approximate $1.0 million cash balance as of the date of this filing, but that is insufficient to complete the development and commercialization of any of our proposed products. We expect to incur costs of approximately $1.8 million in the upcoming fiscal year ending June 30, 2024 to operate our business in accordance with our business plans and budgets.
We have limited experience in drug and formulation development, the conduct of clinical trials, and may not be able to successfully develop any drugs.
Development of pharmaceutical products is a risky and time-consuming process subject to a number of factors, many of which are outside of our control. We are subject to regulatory authority permissions and approvals, most importantly the FDA. Our drug candidate(s)/indications are at early and mid-stages of development. Consequently, we can provide no assurance of the successful and timely development of new drugs, and the failure to do so could cause us to cease operations.
We may elect to deregister our common stock under the Exchange Act and suspend our reporting obligations. Such deregistration and suspension would result in less disclosure about us and may negatively affect the liquidity and trading prices of our common stock.
http://www.ipharminc.com/
About Innovation Pharmaceuticals Inc.:
Established in 2007, and headquartered in Wakefield, Massachusetts, Innovation Pharmaceuticals Inc. (formerly Cellceutix Corporation) is a publicly traded biopharmaceutical company dedicated to discovering and advancing innovative medical therapies with dermatology, oncology, anti-inflammatory and antibiotic applications.
Through ongoing research and drug development efforts, Innovation is focused on improving the clinical care of patients, as well as growing shareholder value. Our team consists of a diverse and accomplished group of professionals working together toward achieving this common goal.
IPIX CEO - "The Company historically devoted most of its efforts and resources on business development, regulatory matters, and clinical trials. Presently, the Company does not have sufficient financial resources to advance our drug candidates meaningfully." "In general, we expect to concentrate on product development and engage in a limited way in product discovery, avoiding the significant investment of time and financial resources that is generally required for a promising compound to be identified and brought into clinical trials." Source - https://www.sec.gov/ix?doc=/Archives/edgar/data/1355250/000147793223003414/ipix_10q.htm
More information is available at http://www.ipharminc.com.
Management: http://www.ipharminc.com/senior-management/
Scientific Advisors: http://www.ipharminc.com/scientific-advisors/
Clinical Trials: https://clinicaltrials.gov/ct2/results?cond=&term=%22Innovation+Pharmaceuticals%2C+Inc.%22++&cntry=&state=&city=&dist=&Search=Search&flds=abcefgps
Trials under previous name: https://clinicaltrials.gov/ct2/results?cond=&term=cellceutix&cntry=&state=&city=&dist=&Search=Search&flds=abcefgps
Product Pipeline: http://www.ipharminc.com/therapeutic-areas/
Recent News and Press Releases:
https://finance.yahoo.com/quote/IPIX?p=IPIX
http://www.ipharminc.com/press-release/
SEC Filings (CIK:0001355250): https://www.sec.gov/cgi-bin/browse-edgar?company=Innovation+Pharmaceutical&owner=exclude&action=getcompany
Transfer Agent:
West Coast Stock Transfer, Inc.
721 N. Vulcan Ave. Ste. 205
Encinitas, CA 92024
(619) 664-4780 p
(760) 452-4423 f
cs@wcsti.com
http://www.westcoaststocktransfer.com
Share Structure: See SEC filing link above for current share structure
Investor Relations:
http://www.ipharminc.com/new-faq/
http://www.ipharminc.com/contact-us-1
Chart: https://stockcharts.com/h-sc/ui?s=IPIX
All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.
Also, keep in mind that moderators may or may not have a position in said stock. Being a moderator isn’t a sign of endorsement.
Please keep your posts on topic because your message(s) will probably be deleted when:
* Posting content that's off-topic to the subject of this board;
* Posting statements that don't add value to the discussion; or
* When you violate any other posting term of the iHub User Agreement: http://investorshub.advfn.com/boards/complex_terms.asp
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |